GNCA - Earnings call transcript Q4 2021 | Genocea Biosciences, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, and welcome to the Genocea Fourth Quarter 2021 Conference Call. [Operator Instructions]. Please be advised that this call is being recorded at the company's request. At this time, I'd like to turn the call over to Daniel Ferry of LifeSci Advisors. Please proceed.

Daniel Ferry

good and operator, you, morning, everyone. Thank we topics we today, issued a the outlines that release plan press Earlier to today. discuss is release tab. available genocea.com under This the at Investors

provide Clark, Joining today, Officer, open the Diantha the the President prepared a review Financial brief will results. and company's the Chief corporate Chip CEO, financial call Duvall, remarks, and update; will will After we Stapleton, Scientific Medical Q&A. Technology Ray up Diantha; Chief Flechtner, Chip; then for will questions. available Chief Genocea's And answer Officer; the Officer; Genocea's be Chief call Davis; Tom Jessica your and Officer, to

or on It to in statements annual as a now any on result periodic of filed and presentation. presentation pass reports Genocea Chip. Participants to including its its presentation to forward-looking statements statements, the to and whether Exchange Securities the I/IIa projected set Securities other and and risks safe Reform including PLANET the this begin, duty over differ forward-looking we and from to otherwise. forward-looking clinical the events subject statements. statement of related Inhibigens. under statements Genocea's and are to those as are anticipated call results The Private is timing Before expressly materially directed All efforts, protection Form trial, Reform XXXX, with to date of of in is XX-K Phase intended Genocea's Act. website. such factors provided information, with Act such the process forward-looking speak ATLAS contains actual outcomes from as manufacturing disclaims pleasure subject the uncertainties, in available report statements and original of only by risk this GEN-XXX defined the this forward-looking harbor provide be my future regard updates research the could and new forth top Each and the to to XXXX Commission Litigation results line to

William Clark

Thanks, with cell thank clinical you for joining share neoantigen-targeted revealed all product Genocea's I'm which trial progress Most therapy us TITAN you. we from soon GEN-XXX, Dan, T for recently today. our share is our results we'll peripheral and candidate. notably, initial pleased to that

that through remind me our of patient's NPTs, a cells comprised each audience we and the patient-specific with platform. derived GEN-XXX screen neoantigen-specific bioassay, is The Let pro-tumor or peripherally for identifies platform ATLAS anti-tumor that neoantigens Inhibigens. neoantigens T

specific antitumor Our PLANET process T identified neoantigens. cells to selectively ATLAS expands the

across had released process, patient entered successfully have administered XX; in available drug continue Of a have patients. process. samples, GEN-XXX with or a XX of of to screening either neoantigens the these have both X, with yielded for X. need. across XX XX patient the XXX% remaining X cohorts multidose a to products, the From XX with ATLAS. As XX an there, across prioritized we the ATLAS average X has range Inhibigens identified On and patient XX X XX X been the March completed single-dose samples patients -- and manufactured of dosing samples upon to average, with rather range PLANET product, drug

initial share first the the AACR. data to expect We presentation poster principally X at patients in from

manufacturing posters color AACR. provide GEN-XXX characteristics. One also the on drug at other present will will PLANET product We X additional and process

selection Inhibigen The evolution by capabilities story ATLAS. made of the other will the showcase neoantigen possible of continued the

X investor covering planning during call Finally, all presentations. AACR an host we to are

of to I'm our John pleased Board Officer timing will announce Directors. at Adaptimmune Chief welcome We Lunger, the Patient exact Supply also shortly. to

goes, As the processes adage product.

invaluable am confident to expertise like also John's successful Board. driver January, would that to So will delivery our success, and with our and critical you and remind drug prove in of long-term us of I product scale-up candidates, a one experiences of neoantigens Pharmaceutical of and Inhibigens Inc., collaboration R&D the therapies an Johnson, companies explore into immunogenicity Johnson vaccine & of entered of we the cancer. option in impact to for of Janssen Janssen Biotech, the and context with the agreement I

So on questions. their I fronts. as up Genocea grateful opening many heart, we the for over the from things, to call our agility. Diantha including to to now the quarter you to multiple to team continue am make tenacity see, I'm Diantha? progress financials can and pass summarize before call going this to

Diantha Duvall

$XX.X $XX.X and Chip, XXXX. December XX, quarter We of with equivalents morning, compared you, Thank and million the everyone. with ended cash million cash good at

Our the as XXXX follows. quarter XX, for operating are ended results December

$XX.X for December net Our compared -- X same the million XXXX, to in XX was million XX was period XX, the loss for $XX December months ended XXXX.

year The period expenses the due for to $X.X $XX.X December same in by tax million million December compared the ended ended XXXX, increase XX, the period costs. XX, in in for same offset $X.X for due impact for compared for million XX, in is due $XX.X operations by professional for to same decreased XXXX, $XX.X to ended for December $X.X both R&D the offset the December to the G&A The were XXXX for in The period partially same facility-related the XXXX, ended million year were decrease XX, XXXX. payroll were $X.X manufacturing quarter clinical a the expenses increase to expenses million R&D December other the GEN-XXX periods for December the ended to adjustment for for in XX, in The million growth compared Our ended XXXX. for net credit. G&A current $XX.X December G&A in partially the Other ended by period the costs, $XX.X XXXX. income was mainly XX, in mainly the mainly for a same G&A existing period G&A December Other XXXX increases our compared is period months XXXX. ended expenses R&D XXXX, expenses million December sufficient the XX, year to XXXX. and decrease The million is clinical increase year noncash internal the R&D other $XX.X million mainly the and quarter is million same our income mainly was the quarter GEN-XXX the for nonrecurring for compared XXXX. XX, is costs. Genocea's expenses cash XXXX, XXXX. fair-value period $XX of in to year to $X.X expense year income support for loss same XXXX. December headcount-related for XX, X costs, million team, in ended facility-related was million manufacturing a XXXX, XXXX, XX, million services. to compared is in warrants. our in for XXXX, for into due XX, expenses $X.X offset the in ended compared for million expenses quarter due to to $XX QX were the December liability-classified XXXX, of costs ended to partially

plans to XXXX. strategic now questions. have let's call operations our that, open for the we With into Operator? up extend However,

Operator

[Operator Instructions].

Our first Stifel. of question comes from Ben Burnett

Benjamin Burnett

I a the AACR. dosed. see update X patients -- guess could These mentioned that X data there chance for at be could expected of an some first we Is have as been X patients question, well? you

William Clark

for question. the thanks Ben,

early on the it data, and safety the a have tolerability too may we tumor. think be will impact but have to clinical I of sense

Benjamin Burnett

the your these for for potential just do Understood. view a patient slightly bar -- you also populations talked there's And or the see to like enroll of in success disease you've for view efficacy the being different think these between the cohorts? also severity, cohorts different hear different like to Okay. in cohorts? about what's past bar X in that I'd I terms X is

William Clark

for cohorts how we Thanks and Ben. think Yes. for ask Tom the dosing X about I'll potential then question, frame the the to rationale success.

Thomas Davis

a question. Obviously, good Chip. Thanks,

the As lymphodepletion, these is aware, they're particularly these some patients the be design there low-dose many eligible again, generally allowed study to TIL intense the patients regimen. infusion cell If multi may arm, combination and of the that of Many in exciting, IL-X. you patients regimen full are full are course, for not see it regimen because less which a who very unable that activity arm. we are capacity any is low-dose and multi patients, think tolerate tolerate I that TIL, a receive, have of we our the don't will complex if to knowing in be essentially receiving the regimen, that for

regimen an hopefully, the full any as we all However, intent, would good setting. that This see the treatment. the range should the us responses. TIL tumor the of And course. we'll and early And see give is this potential expect adjustments in dosing regimen, data set, full of way, potency in along of which a is we TIL sense a for give to

the just seeing be to were going patients are treated. you So initial who

Benjamin Burnett

Understood. Okay. That's helpful.

Operator

Baird. question Kusy comes Colleen from next of Our

Colleen Kusy

Great. Congrats on all the progress.

point patients X tumor types are might you'll multiple that, that you tumor could data at able the there say one have? have to be this whether on, what for can't And you indicate So type? of if you they say

William Clark

in for but will of course, share that all Thanks, a We'll more types. it of tumor about detail, Colleen, multiple month question. in the be

Colleen Kusy

Okay. Great. expect And AACR? we can how long from of the updated a follow-up

William Clark

handle you Yes. Tom, please? why that, don't

Thomas Davis

for been Well, some patients have now time. dosing we

of spectrum cell So across And with that's the of resistance key it's infusion which there the but cells from will patients, remember to important. to really the time, future. the over that be these response define patients durability really proliferation most be those safe the stretches initial going in in the hurdles can therapies

for of be able you a potential the that a will there GEN-XXX. sense that data amount good of So give we'll share is to

Colleen Kusy

is XX Okay. manufacturing to the Great. have some the reason? guess Or run other samples -- not for runs, yet? just I the And delta is Are you've speak and you can there those -- started That's for between that that? the helpful. that ATLAS XX

William Clark

I'll question, Probably handle please. have that Yes. Jess

Jessica Flechtner

it's the Yes, all there -- of above.

is question astute. your very So

and and We process have have into been screened are in that forward several manufacturing. going

the where not have have withdraw did screens some have the happened, to move chosen either but in patients or study. the forward consent We

it's so a combination And factors. of

Colleen Kusy

just terms patients last with or are dosed guess is they they could is Okay. when these I will remind state have for be get disease question. in different of GEN-XXX? disease in their tumors patients the when possible you helpful. And That's state? what of protocol these us progressing it Can kind dosed all

William Clark

question a Tom. you, That's for

Thomas Davis

Chip. Thanks,

refractory, bridging but themselves selected them we being then a we So patients ultimately or we before maintain they've do if chemotherapy, on necessary, manufacturing period defined some dose. regimen and have other are as the when

be disease. it So of the short a answer with a different patients mixture will stage of is

Some of will therapies these prior will refractory. received patients be multiple newly have and others

Operator

of question Gil Company. & next from Blum Needham comes Our

Gil Blum

Thanks update, for questionable AACR. coming up another at question. the news I Maybe and think

to going data considering some tumor tissue X original any have at data, going look tumor-infiltrating we're tissues, these from mean patients, are But that? to So we patients. some I responses. to do things and going discuss see we're lymphocytes assuming I'm you biomarker like like things from

William Clark

Gil, thanks characterize would Jess, likely for what the we'll you question. see?

Jessica Flechtner

Yes.

will biomarker we data. So some presenting be

looking proliferation in We cells have work phenotype of the and ongoing, persistence or some the at periphery.

some point infiltration. I data that we at may have include. we availability biomarkers ongoing We TCR the are but is and to sequencing We tumor should to for work have serum that be able and it data we to anticipate. that do of look can't you the presentation generating

Operator

Our Joe next of Pantginis comes Wainwright. H.C. from question

Joseph Pantginis

I frame see cohorts. the about more dosing I if way, want little to a rationale right question the about this X the can

you doses So I X since your T lower say, while antigenic at in data or fractional effective over internal to get it response rationale time an not still the look lymphodepletion having around you're you yield, an multiple support cells guess, doses, cohort to potentially ThX I load that call regulatory sort these lymphodepleting. of efficient guess you can when without

William Clark

speak going -- rather, I'm Tom, speak to Joe. Thanks, to have Yes. that.

Thomas Davis

a we they good where be I've opportunity have effective Well, full induce able and showing cells provide for in more Joe, regimen this toxicity do could disease. or tumor compromising also But is with we as I the control able that would question. the penetrate we biology intense emphasized to the key But provide main show before, the But is we of if can patients. less while being regimen activity I said have recall, know would could are responses and patients have certainly able hence, And and before, the complex, to otherwise you with to friendlier, circulating you message, TIL-type limited for we but should advanced would regimen. the periphery, who as would our that multi X as arm, many like immune generate the responses, is cohorts is obviously, the to the way can to the that would that a breakthrough, be we high test. dose some be lower functioning. It to more can't low-dose patients simply and, disease their intended the patients be dose. as dose, take a perhaps who goal cells really dose And ultimately

Joseph Pantginis

Got color, it. And appreciate the Tom. I

Chip I these cohorts for it So safety the I patients X X the we'll to you which the well, see even is think guess, going be, patients of and answer next additional of tolerability, But they and to as breakdown can patients are in? now month. share

William Clark

the Yes. two were first the second first next and Joe, per are cohort. in in cohort patients X protocol that the

Joseph Pantginis

just provided Got but to of of separate though. and sort briefly a it. that plans parts potentially teaser operational Got -- with A regard strategic to guess little runway. X it. And extend I update Diantha the the independent bit

Is there regard able a some nondilutive potential of bit guess. a to in deduce maybe to -- arrangements, there's discussion? that couple hopefully, I a there's types one obviously, spectrum plans, So with of

William Clark

lots variety a of fronts. of are discussions on There

specifically And not address we so this going ways about might which hand tip transition. to in we're conversation the that in our particular

Joseph Pantginis

of Of other And course, GEN-XXX to of right of than didn't is quo then a with I any Is and enrollment now sort if -- sort how I going be follow-up? ask as just potential remiss would separately. there status course.

William Clark

Yes. -- -- long-term able continue future. in an to that's on be share and follow-up we hope No, with to update the that it's near

Operator

questions closing to call I'd over showing I'm the turn to at further no time. this Clark like for Chip any remarks. back

William Clark

today. and operator, thanks Thank everyone, joining for us you, again,

Operator

today's conclude you. Ladies does participating. this you Thank for all gentlemen, conference. and Thank

You may day. Have a now disconnect. great

Genocea Biosciences (GNCAQ) 10 Mar 222021 Q4 Earnings call transcript